Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy
详细信息 查看全文
- 作者：Laurè ; ne Leclair-Visonneaua ; b ; c ; 1 ; Tiphaine Rouauda ; b ; 1 ; Bé ; rangè ; re Debillyd ; Franck Durifd ; Jean-Luc Houetoe ; Alexandre Kreislerf ; Luc Defebvref ; Estelle Lamya ; b ; Christelle Volteaug ; Jean-Michel Nguyeng ; Sé ; verine Le Dilya ; Philippe Damiera ; b ; Claire Boutoleau-Bretonniè ; rea ; b ; Pascal Lejeuneh ; Pascal Derkinderena ; b ; derkinderenp@yahoo.fr" class="auth_mail" title="E-mail the corresponding author ; pascal.derkinderen@chu-nantes.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Progressive supranuclear palsy ; Sodium valproate ; Neuroprotection ; Controlled-trial
- 刊名：Clinical Neurology and Neurosurgery
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：146
- 期：Complete
- 页码：35-39
- 全文大小：648 K
文摘
- class="listitem" id="list_lis0005">
- class="label">•
Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP.
- class="label">•
We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP.
- class="label">•
VPA was not effective as a disease-modifying agent in PSP.